Compare Stocks

Alcanna Inc. engages in the retailing of alcohol in North America. The company retails wines, beers, and spirits; and cannabis products It operates 176 locations in Alberta and British Columbia; and 53 cannabis retail stores in Alberta, Ontario, and Saskatchewan. The company was formerly known as Liquor Stores N.A. Ltd. and changed its name to Alcanna Inc. in May 2018. Alcanna Inc. was founded in 2004 and is headquartered in Edmonton, Canada. As of March 30, 2022, Alcanna Inc. operates as a subsidiary of Sundial Growers Inc.

First Trust Morningstar Dividend Leaders Index Fund, seeks investment results that correspond generally to the price and yield of an equity index called the Morningstar Dividend Leaders Index (the Index). The Fund will invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the Index. The objective of the Index is to offer investors a benchmark for dividend portfolios, as well as a means to invest in a portfolio of stocks that have a consistent record of growing dividends, as well as the ability to sustain them. At the annual rebalance date each June, the Index consists of the top 100 stocks, based on dividend yield, of the securities listed on one of the three exchanges (the New York Stock Exchange, the NYSE Amex or NASDAQ) that have been selected through the application of Morningstar, Inc.'s multi-step screening process. The Fund's investment advisor is First Trust Advisors L.P.

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.